Scholarlink

<p>Confirming the antiplatelet effects of P2Y12 inhibitors is clinically important; although various methods exist for evaluating such antiplatelet effects, standard protocols are currently unavailable. We compared four platelet function tests in neuroendovascular patients performed based on two systems: (i) ADP-induced platelet aggregation level (APAL) and (ii) 10 µM ADP maximum aggregation (MA) using CN-6000, and (iii) P2Y12 reaction unit (PRU) as well as (iv) %inhibition using VerifyNow. Retrospective data of all 124 patients (median age 72 [26–92] years; 58.9% male) who received periprocedural antiplatelet therapy for elective neuroendovascular treatments between September 2020–December 2023 were evaluated. Blood samples were acquired the day before, immediately (1–3 days), and 1 month postoperatively, and during bleeding or thrombotic events. The results revealed changes over time in PRU, %inhibition, and APAL values, but not in 10 µM ADP MA. The correlation coefficient for PRU, the most widely used test in this setting, was higher with APAL (<i>r</i> = 0.55, <i>p</i> &lt; 0.01) than with 10 µM ADP MA (<i>r</i> = 0.42, <i>p</i> &lt; 0.01). An APAL result of 8.3 was equivalent to a PRU value of 240. In conclusion, APAL may provide more reliable monitoring of antiplatelet effects than 10 µM ADP MA-based monitoring and is worthy of further evaluation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative study of four platelet function tests conducted using two systems in neuroendovascular patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月29日

查看全文
  • Tasuku Sakayori,
  • Ryosuke Nakanishi,
  • Kenji Shoda,
  • Yoshihiko Ueno,
  • Ayumu Kanbe,
  • Aki Oka,
  • Daisuke Mizutani,
  • Keisuke Kitano,
  • Ryosuke Kikuchi,
  • Yukiko Enomoto

摘要

Confirming the antiplatelet effects of P2Y12 inhibitors is clinically important; although various methods exist for evaluating such antiplatelet effects, standard protocols are currently unavailable. We compared four platelet function tests in neuroendovascular patients performed based on two systems: (i) ADP-induced platelet aggregation level (APAL) and (ii) 10 µM ADP maximum aggregation (MA) using CN-6000, and (iii) P2Y12 reaction unit (PRU) as well as (iv) %inhibition using VerifyNow. Retrospective data of all 124 patients (median age 72 [26–92] years; 58.9% male) who received periprocedural antiplatelet therapy for elective neuroendovascular treatments between September 2020–December 2023 were evaluated. Blood samples were acquired the day before, immediately (1–3 days), and 1 month postoperatively, and during bleeding or thrombotic events. The results revealed changes over time in PRU, %inhibition, and APAL values, but not in 10 µM ADP MA. The correlation coefficient for PRU, the most widely used test in this setting, was higher with APAL (r = 0.55, p < 0.01) than with 10 µM ADP MA (r = 0.42, p < 0.01). An APAL result of 8.3 was equivalent to a PRU value of 240. In conclusion, APAL may provide more reliable monitoring of antiplatelet effects than 10 µM ADP MA-based monitoring and is worthy of further evaluation.